



10 Oktober 2023
10 October 2023
P.U. (A) 306

WARTA KERAJAAN PERSEKUTUAN

*FEDERAL GOVERNMENT
GAZETTE*

PERINTAH RACUN (PINDAAN SENARAI RACUN)
(NO. 2) 2023

*POISONS (AMENDMENT OF POISONS LIST)
(NO. 2) ORDER 2023*

DISIARKAN OLEH/
PUBLISHED BY
JABATAN PEGUAM NEGARA/
ATTORNEY GENERAL'S CHAMBERS

AKTA RACUN 1952

PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2023

PADA menjalankan kuasa yang diberikan oleh seksyen 6 Akta Racun 1952 [*Akta 366*], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut:

Nama

1. Perintah ini bolehlah dinamakan **Perintah Racun (Pindaan Senarai Racun) (No. 2) 2023**.

Pindaan Jadual Pertama

2. Akta Racun 1952 dipinda dalam Jadual Pertama—

(a) dalam Senarai Racun—

- (i) dengan memasukkan selepas butiran “Abiraterone” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Acalabrutinib	-	All preparations”;				

- (ii) dengan menggantikan butiran “Amfepramone; its salts” dengan butiran “Amfepramone”;
- (iii) dengan menggantikan butiran “Aminorex; its salts” dengan butiran “Aminorex”;
- (iv) dengan memasukkan selepas butiran “Avanafil” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Avelumab	-	All preparations”;				

- (v) dengan menggantikan butiran “Barbituric acid and other substances structurally derived therefrom; their compounds; their salts” dengan butiran “Barbituric acid”;
- (vi) dengan memasukkan selepas butiran “Benzocetamine; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"1,4-Benzodiazepine unless specified elsewhere in the List	-	All preparations";				

- (vii) dengan menggantikan butiran "Benzphetamine; its salts" dengan butiran "Benzphetamine";
- (viii) dengan menggantikan butiran "2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine(25B-NBOMe)" dengan butiran "2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe) (DD)";
- (ix) dengan menggantikan butiran "Buprenorphine; its salts" dengan butiran "Buprenorphine";
- (x) dengan memasukkan selepas butiran "Butropium; its salts" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Tert-Butyl 4-(phenylamino)piperidine-1-carboxylate (1-boc-4-AP)	-	-	-	All preparations";		

- (xi) dengan memasukkan selepas butiran "Candesartan; its salts" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Cannabidiol	-	All preparations";				

- (xii) dengan memasukkan selepas butiran "Capecitabine" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Capmatinib	-	All preparations";				

- (xiii) dengan menggantikan butiran “2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine(25C-NBOMe)” dengan butiran “2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe) (DD)”;
- (xiv) dengan memotong butiran “Diazepam and other substances structurally derived from 1, 4-benzodiazepine; their salts, unless specified elsewhere in the List” dan butir-butir yang berhubungan dengannya;
- (xv) dengan memasukkan selepas butiran “Dinitrothymols” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Diphenidine	-	All preparations”;				

- (xvi) dengan memasukkan selepas butiran “Disodium clodronate” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Disodium edetate	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C";

(xvii) dengan memasukkan selepas butiran "Entecavir" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Entrectinib	-	All preparations";				

(xviii) dengan memasukkan selepas butiran "Erythropoietin" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Esafoxolaner	-	All preparations";				

- (xix) dengan menggantikan butiran “N-Ethylamphetamine; its salts” dengan butiran “Ethylamphetamine”;
- (xx) dengan memasukkan selepas butiran “Etryptamine; its salts (DD)” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Eutylone (DD)	-	All preparations”;				

- (xxi) dengan menggantikan butiran “Fluorides, alkali; organo fluorides” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Fluorides, alkali; organo fluorides	-	-	All medicinal preparations containing 3% and over	3% and over Sodium Silicofluoride or Sodium Fluoride unless in Group C	-	All preparations other than those in Group C or Group D”;

- (xxii) dengan memasukkan selepas butiran “Granisetron; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Grapiprant	-	All preparations”;				

- (xxiii) dengan memasukkan selepas butiran “Imiquimod” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Inclisiran	-	All preparations”;				

- (xxiv) dengan menggantikan butiran “2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe)” dengan butiran “2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe) (DD)”;

- (xxv) dengan memasukkan selepas butiran “Labetalol; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Labuvirtide	-	All preparations";				

(xxvi) dengan menggantikan butiran "Lefetamine or SPA or (-)-1-dimethyl-amino-1, 2-diphenylethane" dengan butiran "Lefetamine";

(xxvii) dengan memasukkan selepas butiran "Leflunomide; its salts" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Lemborexant	-	All preparations";				

(xxviii) dengan memasukkan selepas butiran "Lung Phospholipid" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Lurasidone	-	All preparations";				

(xxix) dengan memasukkan selepas butiran “Luseogliflozin” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Luspatercept	-	All preparations”;				

(xxx) dengan memasukkan selepas butiran “5-Methoxy-N,N-methylisopropyltryptamine” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“3-Methoxyphencyclidine (3-MeO-PCP)	-	All preparations”;				

(xxxi) dengan memasukkan selepas butiran “4-Methylbuphedrone” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Methyl 3, 3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate (MDMB-4en-PINACA) (DD)”	-	All preparations”;				

(xxxii) dengan memotong butiran “Methyl (2S)-2-{{1-(5-fluoropentyl)-1H-indazole-3-carbonyl}amino}-3,3-dimethylbutanoate (5F-ADB/5F-MDMB-PINACA) (DD)” dan butir-butir yang berhubungan dengannya;

(xxxiii) dengan memasukkan selepas butiran “4-Methylethcathinone (4-MEC)” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Methyl (2S)-2-{{1-(5-fluoropentyl)-1H-indazole-3-carbonyl}amino}-3,3-dimethylbutanoate (5F-ADB/5F-MDMB-PINACA) (DD)”	-	All preparations”;				

- (xxxiv) dengan memotong butiran “3-Methylmethcathinone (3-MMC)” dan butir-butir yang berhubungan dengannya;
- (xxxv) dengan memotong butiran “Methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (AMB-FUBINACA)” dan butir-butir yang berhubungan dengannya;
- (xxxvi) dengan memasukkan selepas butiran “3,4-MDP-2-P Methyl glycidic acid (PMK glycidic acid)” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“3-Methylmethcathinone (3-MMC)	-	All preparations”;				

- (xxxvii) dengan menggantikan butiran “Methylphenidate; its salts” dengan butiran “Methylphenidate”;
- (xxxviii) dengan memasukkan selepas butiran “Mofebutazone” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Molnupiravir	-	All preparations";				

(xxxix) dalam senarai "Monoclonal antibody; includes the following:"—

- (A) dengan memasukkan selepas butiran "Brolucizumab" butiran "Burosumab";
 - (B) dengan memasukkan selepas butiran "Canakinumab" butiran "Casirivimab";
 - (C) dengan memasukkan selepas butiran "Evolocumab" butiran "Faricimab";
 - (D) dengan memasukkan selepas butiran "Idarucizumab" butiran "Imdevimab";
 - (E) dengan memasukkan selepas butiran "Ranibizumab" butiran "Regdanvimab";
 - (F) dengan memasukkan selepas butiran "Sarilumab" butiran "Satralizumab"; dan
 - (G) dengan memasukkan selepas butiran "Siltuximab" butiran "Sotrovimab";
- (xl) dengan menggantikan butiran "Nalbuphine; its salts" dengan butiran "Nalbuphine":

(xli) dalam senarai “Narcotic substances; the following:”—

(A) dengan memasukkan selepas butiran “(DD) 4-bromo-2, 5-dimethoxyphenethylamine (2C-B)” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) Brorphine	-	All preparations”;				

(B) dengan memasukkan selepas butiran “(DD) 1-Methyl-4-phenyl-4-piperidinol propionate (MPPP)” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) Metonitazene	-	All preparations”;				dan

(C) dengan memasukkan selepas butiran “(DD) Isomethadone” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) Isotonitazene	-	All preparations”;				

(xlii) dengan memasukkan selepas butiran “Nintedanib” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Nirmatrelvir	-	All preparations”;				

(xliii) dengan menggantikan butiran “Nitric Oxide” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Nitric Oxide"	-	Preparations in the form of medicinal gas for therapeutic use	-	-	-	(1) All preparations unless in Group B (2) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived";

(xliv) dengan memasukkan selepas butiran "Norephedrine" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Norfentanyl	-	-	-	All preparations";		

- (xlv) dengan memasukkan selepas butiran "Nortriptyline; its salts" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Nusinersen	-	All preparations";				

- (xlvi) dengan memasukkan selepas butiran "Nystatin" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Oclacitinib	-	All preparations";				

- (xlvii) dengan memasukkan selepas butiran "Pegabtanib Sodium" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Pegaspargase	-	All preparations";				

(xlvi) dengan memasukkan selepas butiran "Pegvisomant" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Pemafibrate	-	All preparations";				

(xlix) dengan menggantikan butiran "Pemoline; its salts" dengan butiran "Pemoline";

(l) dengan menggantikan butiran "Pentazocine; its salts" dengan butiran "Pentazocine";

(li) dengan memasukkan selepas butiran "(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) (DD)" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“5-Pentyl-2-(2-phenylpropan-2-yl)-2,5-dihydro-1H-pyrido[4,3-b]indol-1-one (CUMYL-PEGACLONE)(DD)	-	All preparations”;				
(lii)	dengan menggantikan butiran “Phencyclidine; its salts” dengan butiran “Phencyclidine”;					
(liii)	dengan menggantikan butiran “Phendimetrazine; its salts” dengan butiran “Phendimetrazine”;					
(liv)	dengan menggantikan butiran “Phenmetrazine; its salts” dengan butiran “Phenmetrazine”;					
(lv)	dengan menggantikan butiran “Phentermine; its salts” dengan butiran “Phentermine”;					
(lvi)	dengan memasukkan selepas butiran “Phenylene-1, 4-diisothiocyanate” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:					

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"N-Phenyl-4-piperidinamine (4-AP)	-	-	-	All preparations";		

(lvii) dengan memasukkan selepas butiran "Pimecrolimus" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
"Pimobendan	-	All preparations";					

(lviii) dengan menggantikan butiran "Piperidine" dengan butiran "Piperidine unless specified elsewhere in the List";

(lix) dengan menggantikan butiran "Pipradrol; its salts" dengan butiran "Pipradrol";

(lx) dengan memasukkan selepas butiran "Plerixafor" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Polidocanol	-	All preparations for parenteral administration	-	-	-	All preparations unless in Group B";

(lxi) dengan memasukkan selepas butiran "Propantheline; its salts" dan butir-butir yang berhubungan dengannya butir dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Propiverine	-	All preparations";				

(lxii) dengan menggantikan butiran "Propylhexedrine; its salts" dengan butiran "Propylhexedrine";

(lxiii) dengan memasukkan selepas butiran "Rasburicase" dan butir-butir yang berhubungan dengannya butir dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Ravidasvir	-	All preparations";				

- (lxiv) dengan memasukkan selepas butiran “Rizatriptan; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Robenacoxib	-	All preparations”;				

- (lxv) dengan memasukkan selepas butiran “Sacubitril” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Safinamide	-	All preparations”;				

- (lxvi) dengan memasukkan selepas butiran “Saquinavir; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Sarolaner	-	All preparations”;				

(lxvii) dengan memotong butiran “Sodium edetate” dan butir-butir yang berhubungan dengannya;

(lxviii) dengan memasukkan selepas butiran “Sodium hydroxide” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Sodium zirconium cyclosilicate	-	All preparations”;				

(lxix) dengan memasukkan selepas butiran “Tadalafil” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Tafamidis	-	All preparations”;				

(lxx) dengan memasukkan selepas butiran “Tafluprost” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Talazoparib	-	All preparations";				

(lxxi) dengan memasukkan selepas butiran "Tetramisole" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Tetrofosmin	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C";

(lxxii) dengan memasukkan selepas butiran "Toltrazuril" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Tolvaptan	-	All preparations";				

(lxxiii) dengan memasukkan selepas butiran "Valaciclovir; its salts" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Valbenazine	-	All preparations";				

(lxxiv) dengan memasukkan selepas butiran "Verapamil; its salts" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Vericiguat	-	All preparations";				

(lxxv) dengan menggantikan butiran "Zinc p-phenolsulphonate" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Zinc p-phenolsulphonate	-	-	Medicinal preparations unless exempted	All preparations other than Group C and exempted	-	Strength of 5% and under";

(lxxvi) dengan menggantikan butiran “Zipeprol; its salts” dengan butiran “Zipeprol”; dan

(lxxvii) dengan menggantikan butiran “Zolpidem; its salts” dengan butiran “Zolpidem”; dan

(b) dalam Lampiran kepada Senarai Racun—

(i) dalam senarai “**Anaesthetics:**”—

(A) dengan memasukkan selepas butiran “Desflurane” butiran “Diphenidine”;

(B) dengan memasukkan selepas butiran “Methoxetamine (MXE)” butiran “3-Methoxyphencyclidine (3-MeO-PCP)”; dan

(C) dengan menggantikan butiran “Phencyclidine; its salts” dengan butiran “Phencyclidine”;

(ii) dalam senarai “**Analeptics and Central Stimulants:**”—

(A) dengan menggantikan butiran “N-Ethylamphetamine; its salts” dengan butiran “Ethylamphetamine”;

(B) dengan memasukkan selepas butiran “Etryptamine (DD)” butiran “Eutylone (DD)”;

- (C) dengan menggantikan butiran “Lefetamine or SPA or (-)-1-dimethylamino-1, 2-diphenylethane” dengan butiran “Lefetamine”;
 - (D) dengan memasukkan selepas butiran “4-Methylbuphedrone” butiran “Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate (MDMB-4en-PINACA) (DD)”;
 - (E) dengan menggantikan butiran “Methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (AMB-FUBINACA)” dengan butiran “Methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (FUB-AMB) (DD)”;
 - (F) dengan menggantikan butiran “Methylphenidate; its salts” dengan butiran “Methylphenidate”;
 - (G) dengan menggantikan butiran “Pemoline; its salts” dengan butiran “Pemoline”; dan
 - (H) dengan menggantikan butiran “Pipradrol; its salts” dengan butiran “Pipradrol”;
- (iii) dalam senarai “**Analgesics including antipyretic and anti-inflammatory agents:**” —
- (A) dengan menggantikan butiran “Buprenorphine; its salts” dengan butiran “Buprenorphine”;
 - (B) dengan memasukkan selepas butiran “Glaphenine” butiran “Grapiprant”;

- (C) dengan menggantikan butiran “Nalbuphine; its salts” dengan butiran “Nalbuphine”;
 - (D) dengan menggantikan butiran “Pentazocine; its salts” dengan butiran “Pentazocine”; dan
 - (E) dengan memasukkan selepas butiran “Rizatriptan; its salts” butiran “Robenacoxib”;
- (iv) dalam senarai “**Anorectics:**”—
- (A) dengan menggantikan butiran “Amfepramone; its salts” dengan butiran “Amfepramone”;
 - (B) dengan menggantikan butiran “Aminorex; its salts” dengan butiran “Aminorex”;
 - (C) dengan menggantikan butiran “Benzphetamine; its salts” dengan butiran “Benzphetamine”;
 - (D) dengan menggantikan butiran “Phendimetrazine; its salts” dengan butiran “Phendimetrazine”;
 - (E) dengan menggantikan butiran “Phenmetrazine; its salts” dengan butiran “Phenmetrazine”;
 - (F) dengan menggantikan butiran “Phentermine; its salts” dengan butiran “Phentermine”; dan
 - (G) dengan menggantikan butiran “Propylhexedrine; its salts” dengan butiran “Propylhexedrine”;

- (v) dalam senarai “**Anticholinergics:**”, dengan memasukkan selepas butiran “Propantheline; its salts” butiran “Propiverine”;
- (vi) dalam senarai “**Anticonvulsants:**”, dengan memasukkan selepas butiran “Beclamide” butiran “Cannabidiol”;
- (vii) dalam senarai “**Antineoplastic agents and Immunosuppressants:**”—
 - (A) dengan memasukkan selepas butiran “Abiraterone” butiran “Acalabrutinib”;
 - (B) dengan memasukkan selepas butiran “Atezolizumab” butiran “Avelumab”;
 - (C) dengan memasukkan selepas butiran “Capecitabine” butiran “Capmatinib”;
 - (D) dengan memasukkan selepas butiran “Carmustine; its salts” butiran “Casirivimab”;
 - (E) dengan memasukkan selepas butiran “Durvalumab” butiran “Entrectinib”;
 - (F) dengan memasukkan selepas butiran “Idelalisib” butiran “Imdevimab”;
 - (G) dengan memasukkan selepas butiran “Pazopanib” butiran “Pegaspargase”;

- (H) dengan memasukkan selepas butiran “Sarilumab” butiran “Satralizumab”; dan
- (I) dengan memasukkan selepas butiran “Tacrolimus” butiran “Talazoparib”;
- (viii) dalam senarai “**Antiparkinsonism agents:**”, dengan memasukkan selepas butiran “Rotigotine” butiran “Safinamide”;
- (ix) dalam senarai “**Antiviral agents:**” —
 - (A) dengan memasukkan selepas butiran “Interferons” butiran “Labuvirtide”;
 - (B) dengan memasukkan selepas butiran “Methisoprinol” butiran “Molnupiravir”;
 - (C) dengan memasukkan selepas butiran “Nevirapine; its salts” butiran “Nirmatrelvir”;
 - (D) dengan memasukkan selepas butiran “Pibrentasvir” butiran yang berikut:
 - “Ravidasvir
 - Regdanvimab”; dan

- (E) dengan memasukkan selepas butiran “Sofosbuvir” butiran “Sotrovimab”;
- (x) dalam senarai “**Cardio drugs:**”—
- (A) dengan memasukkan selepas butiran “Oxprenolol; its salts” butiran “Pimobendan”; dan
- (B) dengan memasukkan selepas butiran “Tirofiban” butiran “Vericiguat”;
- (xi) dalam senarai “**Dermatological agents:**”, dengan memasukkan selepas butiran “Methoxsalen” butiran “Oclacitinib”;
- (xii) dalam senarai “**Diuretics:**”, dengan memasukkan selepas butiran “Spironolactone” butiran “Tolvaptan”;
- (xiii) dalam senarai “**Hallucinogens:**”—
- (A) dengan menggantikan butiran “2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe)” dengan butiran “2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe) (DD)”;
- (B) dengan menggantikan butiran “2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe)” dengan butiran “2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe) (DD)”;

- (C) dengan menggantikan butiran “2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe)” dengan butiran “2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe) (DD)”;
- (xiv) dalam senarai “**Hypnotics and sedatives:**”—
- (A) dengan menggantikan butiran “Barbituric acid and other substances structurally derived therefrom; their compounds; their salts” dengan butiran “Barbituric acid”;
- (B) dengan memasukkan selepas butiran “Hexapropymate” butiran “Lemborexant”; dan
- (C) dengan menggantikan butiran “Zolpidem; its salts” dengan butiran “Zolpidem”;
- (xv) dalam senarai “**Industrial and laboratory poisons:**”, dengan menggantikan butiran “Piperidine” dengan butiran “Piperidine unless specified elsewhere in the List”;
- (xvi) dalam senarai “**Narcotics:**”—
- (A) dengan memasukkan selepas butiran “(DD) 4-bromo-2, 5-dimethoxyphenethylamine (2C-B)” butiran “(DD) Brorphine”;

- (B) dengan memasukkan selepas butiran “(DD) Isomethadone” butiran “(DD) Isotonitazene”; dan
- (C) dengan memasukkan selepas butiran “(DD) 1-Methyl-4-phenyl-4-piperidinol propionate (MPPP)” butiran “(DD) Metonitazene”;

(xvii) dalam senarai “**Tranquillisers:**”—

- (A) dengan memasukkan selepas butiran “Benzoctamine; its salts” butiran “1,4-Benzodiazepine unless specified elsewhere in the List”;
- (B) dengan memotong butiran “Diazepam and other substances structurally derived from 1, 4-benzodiazepine; their salts, unless specified elsewhere in the List”;
- (C) dengan memasukkan selepas butiran “Hydroxyzine; its salts” butiran “Lurasidone”; dan
- (D) dengan memasukkan selepas butiran “Tybamate” butiran “Valbenazine”; dan

(xviii) dalam senarai “**Miscellaneous:**”—

- (A) dengan memasukkan selepas butiran “Brucine” butiran berikut:

“Burosumab

Tert-Butyl 4-(phenylamino)piperidine-1-carboxylate (1-boc-4-AP”;

- (B) dengan memasukkan selepas butiran “Disodium clodronate” butiran “Disodium edetate”;
- (C) dengan memasukkan selepas butiran “Ergot, alkaloids of” butiran “Esafoxolaner”;
- (D) dengan memasukkan selepas butiran “Fampridine” butiran “Faricimab”;
- (E) dengan memasukkan selepas butiran “Imiquimod” butiran “Inclisiran”;
- (F) dengan memasukkan selepas butiran “Lung phospholipid” butiran “Luspatercept”;
- (G) dengan memotong butiran “Methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (FUB-AMB) (DD)”;
- (H) dengan memasukkan selepas butiran “Nitrophenols, ortho, meta and para” butiran berikut:

“Norfentanyl

Nusinersen”;

- (I) dengan memasukkan selepas butiran “Pegvisomant” butiran “Pemafibrate”;
- (J) dengan memasukkan selepas butiran “Pentosan” butiran “5-Pentyl-2-(2-phenylpropan-2-yl)-2,5-dihydro-1H-pyrido[4,3-b]indol-1-one (CUMYL-PEGACLONE)(DD)”;
- (K) dengan memasukkan selepas butiran “Phenols (any member of the series of phenols of which the first member is phenol and of which the molecular composition varies from member to member by one atom of carbon and two atoms of hydrogen); compounds of phenol with a metal” butiran “N-Phenyl-4-piperidinamine (4-AP)”;
- (L) dengan memasukkan selepas butiran “Plerixafor” butiran “Polidocanol”;
- (M) dengan memasukkan selepas butiran “Sapropterin” butiran “Sarolaner”;
- (N) dengan memotong butiran “Sodium edetate”;
- (O) dengan memasukkan selepas butiran “Sodium cromoglycate” butiran “Sodium zirconium cyclosilicate”;

- (P) dengan memasukkan selepas butiran “Sumatriptan” butiran “Tafamidis”; dan
- (Q) dengan memasukkan selepas butiran “Teriparatide” butiran “Tetrofosmin”.

Dibuat 13 September 2023
[KKM.600-18/2/95; PN(PU2)172/JLD. 20]

DR. ZALIHA BINTI MUSTAFA
Menteri Kesihatan

POISONS ACT 1952

POISONS (AMENDMENT OF POISONS LIST) (NO. 2) ORDER 2023

IN exercise of the powers conferred by section 6 of the Poisons Act 1952 [*Act 366*], the Minister, after consultation with the Poisons Board, makes the following order:

Citation

1. This order may be cited as the **Poisons (Amendment of Poisons List) (No. 2) Order 2023**.

Amendment of First Schedule

2. The Poisons Act 1952 is amended in the First Schedule—

(a) in the Poisons List—

- (i) by inserting after the item “Abiraterone” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“Acalabrutinib	-	All preparations”;					

- (ii) by substituting for the item “Amfepramone; its salts” the item “Amfepramone”;
- (iii) by substituting for the item “Aminorex; its salts” the item “Aminorex”;
- (iv) by inserting after the item “Avanafil” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Avelumab	-	All preparations”;				

- (v) by substituting for the item “Barbituric acid and other substances structurally derived therefrom; their compounds; their salts” the item “Barbituric acid”;
- (vi) by inserting after the item “Benzoctamine; its salts” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"1,4-Benzodiazepine unless specified elsewhere in the List	-	All preparations";				

- (vii) by substituting for the item "Benzphetamine; its salts" the item "Benzphetamine";
- (viii) by substituting for the item "2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine(25B-NBOMe)" the item "2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe) (DD)";
- (ix) by substituting for the item "Buprenorphine; its salts" the item "Buprenorphine";
- (x) by inserting after the item "Butropium; its salts" and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Tert-Butyl 4- (phenylamino)piperidine-1- carboxylate (1-boc-4-AP)	-	-	-	All preparations";		

(xi) by inserting after the item “Candesartan; its salts” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Cannabidiol	-	All preparations”;				

(xii) by inserting after the item “Capecitabine” and particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Capmatinib	-	All preparations”;				

(xiii) by substituting for the item “2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine(25C-NBOMe)” the item “2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe) (DD)”;

(xiv) by deleting the item “Diazepam and other substances structurally derived from 1,4-benzodiazepine; their salts, unless specified elsewhere in the List” and the particulars relating to it;

(xv) by inserting after the item “Dinitrothymols” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Diphenidine	-	All preparations";				

(xvi) by inserting after the item "Disodium clodronate" and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Disodium edetate	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C";

(xvii) by inserting after the item "Entecavir" and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Entrectinib	-	All preparations";				

(xviii) by inserting after the item “Erythropoietin” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Esafoxolaner	-	All preparations”;				

(xix) by substituting for the item “N-Ethylamphetamine; its salts” the item “Ethylamphetamine”;

(xx) by inserting after the item “Etryptamine; its salts (DD)” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Eutylone (DD)	-	All preparations”;				

(xxi) by substituting for the item “Fluorides, alkali; organo fluorides” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Fluorides, alkali; organo fluorides	-	-	All medicinal preparations containing 3% and over	3% and over Sodium Silicofluoride or Sodium Fluoride unless in Group C	-	All preparations other than those in Group C or Group D”;

(xxii) by inserting after the item “Granisetron; its salts” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Grapiprant	-	All preparations”;				

(xxiii) by inserting after the item “Imiquimod” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Inclisiran	-	All preparations”;				

(xxiv) by substituting for the item “2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe)” the item “2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe) (DD)”;

(xxv) by inserting after the item “Labetalol; its salts” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Labuvirtide	-	All preparations”;				

(xxvi) by substituting for the item “Lefetamine or SPA or (-)-1-dimethyl-amino-1, 2-diphenylethane” the item “Lefetamine”;

(xxvii) by inserting after the item “Leflunomide; its salts” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Lemborexant	-	All preparations”;				

(xxviii) by inserting after the item “Lung Phospholipid” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Lurasidone	-	All preparations”;				

(xxix) by inserting after the item “Luseogliflozin” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Luspatercept	-	All preparations”;				

(xxx) by inserting after the item “5-Methoxy-N,N-methylisopropyltryptamine” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“3-Methoxyphencyclidine (3-MeO-PCP)	-	All preparations”;				

(xxxii) by inserting after the item “4-Methylbuphedrone” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Methyl 3, 3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate (MDMB-4en-PINACA) (DD)	-	All preparations”;				

(xxxii) by deleting the item “Methyl (2S)-2-[[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-ADB/5F-MDMB-PINACA) (DD)” and the particulars relating to it;

(xxxiii) by inserting after the item “4-Methylethcathinone (4-MEC)” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Methyl (2S)-2-{{1 - (5-fluoropentyl)-1H-indazole-3-carbonyl}amino}-3,3- dimethylbutanoate (5F-ADB/ 5F-MDMB-PINACA) (DD)	-	All preparations”;				

(xxxiv) by deleting the item “3-Methylmethcathinone (3-MMC)” and the particulars relating to it;

(xxxv) by deleting the item “Methyl (2S)-2-{{1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (AMB-FUBINACA)” and the particulars relating to it;

(xxxvi) by inserting after the item “3,4-MDP-2-P Methyl glycidic acid (PMK glycidic acid)” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"3-Methylmethcathinone (3-MMC)	-	All preparations";				

(xxxvii) by substituting for the item "Methylphenidate; its salts" the item "Methylphenidate";

(xxxviii) by inserting after the item "Mofebutazone" and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Molnupiravir	-	All preparations";				

(xxxix) in the list of "Monoclonal antibody; includes the following:"—

- (A) by inserting after the item "Brolucizumab" the item "Burosumab";
- (B) by inserting after the item "Canakinumab" the item "Casirivimab";
- (C) by inserting after the item "Evolocumab" the item "Faricimab";

- (D) by inserting after the item “Idarucizumab” the item “Imdevimab”;
 - (E) by inserting after the item “Ranibizumab” the item “Regdanvimab”;
 - (F) by inserting after the item “Sarilumab” the item “Satralizumab”; and
 - (G) by inserting after the item “Siltuximab” the item “Sotrovimab”;
- (xl) by substituting for the item “Nalbuphine; its salts” the item “Nalbuphine”;
- (xli) in the list of “Narcotic substances; the following:” —
- (A) by inserting after the item “(DD) 4-bromo-2, 5-dimethoxyphenethylamine (2C-B)” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) Brorphine	-	All preparations”;				

- (B) by inserting after the item “(DD) 1-Methyl-4-phenyl-4-piperidinol propionate (MPPP)” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“(DD) Metonitazene	-	All preparations”; and					

- (C) by inserting after the item “(DD) Isomethadone” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“(DD) Isotonitazene	-	All preparations”;					

- (xlii) by inserting after the item “Nintedanib” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“Nirmatrelvir	-	All preparations”;					

(xlili) by substituting for the item “Nitric oxide” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Nitric Oxide	-	Preparations in the form of medicinal gas for therapeutic use	-	-	-	(1) All preparations unless in Group B (2) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xlv) by inserting after the item “Norephedrine” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Norfentanyl	-	-	-	All preparations”;		

(xlvi) by inserting after the item “Nortriptyline; its salts” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Nusinersen	-	All preparations”;				

(xlvii) by inserting after the item “Nystatin” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Oclacitinib	-	All preparations”;				

(xlvii) by inserting after the item “Pegabtanib Sodium” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Pegaspargase	-	All preparations”;				

(xlviii) by inserting after the item “Pegvisomant” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Pemafibrate	-	All preparations”;				

(xlix) by substituting for the item “Pemoline; its salts” the item “Pemoline”;

(l) by substituting for the item “Pentazocine; its salts” the item “Pentazocine”;

(li) by inserting after the item “(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) (DD)” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“5-Pentyl-2-(2-phenylpropan-2-yl)-2,5-dihydro-1H-pyrido [4,3-b]indol-1-one (CUMYL-PEGACLONE)(DD)	-	All preparations”;				
(lii)	by substituting for the item “Phencyclidine; its salts” the item “Phencyclidine”;					
(liii)	by substituting for the item “Phendimetrazine; its salts” the item “Phendimetrazine”;					
(liv)	by substituting for the item “Phenmetrazine; its salts” the item “Phenmetrazine”;					
(lv)	by substituting for the item “Phentermine; its salts” the item “Phentermine”;					
(lvi)	by inserting after the item “Phenylene-1, 4-diisothiocyanate” and the particulars relating to it the following item and particulars:					

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"N-Phenyl-4-piperidinamine (4-AP)	-	-	-	All preparations";		

(lvii) by inserting after the item "Pimecrolimus" and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
"Pimobendan	-	All preparations";					

(lviii) by substituting for the item "Piperidine" the item "Piperidine unless specified elsewhere in the List";

(lix) by substituting for the item "Pipradrol; its salts" the item "Pipradrol";

(lx) by inserting after the item "Plerixafor" and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Polidocanol	-	All preparations for parenteral administration	-	-	-	All preparations unless in Group B";

(lxi) by inserting after the item "Propantheline; its salts" and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Propiverine	-	All preparations";				

(lxii) by substituting for the item "Propylhexedrine; its salts" the item "Propylhexedrine";

(lxiii) by inserting after the item "Rasburicase" and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Ravidasvir	-	All preparations";				

(lxiv) by inserting after the item “Rizatriptan; its salts” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Robenacoxib	-	All preparations”;				

(lxv) by inserting after the item “Sacubitril” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Safinamide	-	All preparations”;				

(lxvi) by inserting after the item “Saquinavir; its salts” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Sarolaner	-	All preparations”;				

(lxvii) by deleting the item “Sodium edetate” and the particulars relating to it;

(lxviii) by inserting after the item “Sodium hydroxide” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Sodium zirconium cyclosilicate	-	All preparations”;				

(lxix) by inserting after the item “Tadalafil” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Tafamidis	-	All preparations”;				

(lxx) by inserting after the item “Tafluprost” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Talazoparib	-	All preparations”;				

(lxxi) by inserting after the item “Tetramisole” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Tetrofosmin	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(lxxii) by inserting after the item “Toltrazuril” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Tolvaptan	-	All preparations”;				

(lxxiii) by inserting after the item “Valaciclovir; its salts” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Valbenazine	-	All preparations”;				

(lxxiv) by inserting after the item “Verapamil; its salts” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Vericiguat	-	All preparations”;				

(lxxv) by substituting for the item “Zinc p-phenolsulphonate” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Zinc p-phenolsulphonate	-	-	Medicinal preparations unless exempted	All preparations other than Group C and exempted	-	Strength of 5% and under”;

(lxxvi) by substituting for the item “Zipeprol; its salts” the item “Zipeprol”; and

(lxxvii) by substituting for the item “Zolpidem; its salts” the item “Zolpidem”; and

(b) in the Appendix to the Poisons List—

(i) in the list of “**Anaesthetics:**”—

(A) by inserting after the item “Desflurane” the item “Diphenidine”;

(B) by inserting after the item “Methoxetamine (MXE)” the item “3-Methoxyphencyclidine (3-MeO-PCP)”; and

(C) by substituting for the item “Phencyclidine; its salts” the item “Phencyclidine”;

(ii) in the list of “**Analeptics and Central Stimulants:**”—

(A) by substituting for the item “N-Ethylamphetamine; its salts” the item “Ethylamphetamine”;

(B) by inserting after the item “Etryptamine (DD)” the item “Eutylone (DD)”;

(C) by substituting for the item “Lefetamine or SPA or (-)-1-dimethyl-amino-1, 2-diphenylethane” the item “Lefetamine”;

(D) by inserting after the item “4-Methylbuphedrone” the item “Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate (MDMB-4en-PINACA) (DD)”;

- (E) by substituting for the item “Methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (AMB-FUBINACA)” the item “Methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (FUB-AMB) (DD)”;
 - (F) by substituting for the item “Methylphenidate; its salts” the item “Methylphenidate”;
 - (G) by substituting for the item “Pemoline; its salts” the item “Pemoline”; and
 - (H) by substituting for the item “Pipradrol; its salts” the item “Pipradrol”;
- (iii) in the list of “**Analgesics including antipyretic and anti-inflammatory agents:**” —
- (A) by substituting for the item “Buprenorphine; its salts” the item “Buprenorphine”;
 - (B) by inserting after the item “Glaphenine” the item “Grapiprant”;
 - (C) by substituting for the item “Nalbuphine; its salts” the item “Nalbuphine”;
 - (D) by substituting for the item “Pentazocine; its salts” the item “Pentazocine”; and
 - (E) by inserting after the item “Rizatriptan; its salts” the item “Robenacoxib”;

- (iv) in the list of “**Anorectics:**”—
 - (A) by substituting for the item “Amfepramone; its salts” the item “Amfepramone”;
 - (B) by substituting for the item “Aminorex; its salts” the item “Aminorex”;
 - (C) by substituting for the item “Benzphetamine; its salts” the item “Benzphetamine”;
 - (D) by substituting for the item “Phendimetrazine; its salts” the item “Phendimetrazine”;
 - (E) by substituting for the item “Phenmetrazine; its salts” the item “Phenmetrazine”;
 - (F) by substituting for the item “Phentermine; its salts” the item “Phentermine”; and
 - (G) by substituting for the item “Propylhexedrine; its salts” the item “Propylhexedrine”;
- (v) in the list of “**Anticholinergics:**”, by inserting after the item “Propantheline; its salts” the item “Propiverine”;
- (vi) in the list of “**Anticonvulsants:**”, by inserting after the item “Beclamide” the item “Cannabidiol”;
- (vii) in the list of “**Antineoplastic agents and Immunosuppressants:**”—

- (A) by inserting after the item “Abiraterone” the item “Acalabrutinib”;
 - (B) by inserting after the item “Atezolizumab” the item “Avelumab”;
 - (C) by inserting after the item “Capecitabine” the item “Capmatinib”;
 - (D) by inserting after the item “Carmustine; its salts” the item “Casirivimab”;
 - (E) by inserting after the item “Durvalumab” the item “Entrectinib”;
 - (F) by inserting after the item “Idelalisib” the item “Imdevimab”;
 - (G) by inserting after the item “Pazopanib” the item “Pegaspargase”;
 - (H) by inserting after the item “Sarilumab” the item “Satralizumab”; and
 - (I) by inserting after the item “Tacrolimus” the item “Talazoparib”;
- (viii) in the list of “**Antiparkinsonism agents:**”, by inserting after the item “Rotigotine” the item “Safinamide”;

(ix) in the list of “**Antiviral agents:**”—

(A) by inserting after the item “Interferons” the item “Labuvirtide”;

(B) by inserting after the item “Methisoprinol” the item “Molnupiravir”;

(C) by inserting after the item “Nevirapine; its salts” the item “Nirmatrelvir”;

(D) by inserting after the item “Pibrentasvir” the following items:

“Ravidasvir

Regdanvimab”; and

(E) by inserting after the item “Sofosbuvir” the item “Sotrovimab”;

(x) in the list of “**Cardio drugs:**”—

(A) by inserting after the item “Oxprenolol; its salts” the item “Pimobendan”; and

(B) by inserting after the item “Tirofiban” the item “Vericiguat”;

- (xi) in the list of “**Dermatological agents:**”, by inserting after the item “Methoxsalen” the item “Oclacitinib”;
- (xii) in the list of “**Diuretics:**”, by inserting after the item “Spironolactone” the item “Tolvaptan”;
- (xiii) in the list of “**Hallucinogens:**”—
- (A) by substituting for the item “2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe)” the item “2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe) (DD)”;
- (B) by substituting for the item “2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe)” the item “2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe) (DD)”;
- (C) by substituting for the item “2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe)” the item “2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe) (DD)”;

- (xiv) in the list of **“Hypnotics and sedatives:”**—
- (A) by substituting for the item “Barbituric acid and other substances structurally derived therefrom; their compounds; their salts” the item “Barbituric acid”;
 - (B) by inserting after the item “Hexapropymate” the item “Lemborexant”; and
 - (C) by substituting for the item “Zolpidem; its salts” the item “Zolpidem”;
- (xv) in the list of **“Industrial and laboratory poisons:”**, by substituting for the item “Piperidine” the item “Piperidine unless specified elsewhere in the List”;
- (xvi) in the list of **“Narcotics:”**—
- (A) by inserting after the item “(DD) 4-bromo-2, 5-dimethoxyphenethylamine (2C-B)” the item “(DD) Brorphine”;
 - (B) by inserting after the item “(DD) Isomethadone” the item “(DD) Isotonitazene”; and
 - (C) by inserting after the item “(DD) 1-Methyl-4-phenyl-4-piperidinol propionate (MPPP)” the item “(DD) Metonitazene”;

(xvii) in the list of "**Tranquillisers:**"—

- (A) by inserting after the item "Benzoctamine; its salts" the item "1,4-Benzodiazepine unless specified elsewhere in the List";
- (B) by deleting the item "Diazepam and other substances structurally derived from 1, 4-benzodiazepine; their salts, unless specified elsewhere in the List";
- (C) by inserting after the item "Hydroxyzine; its salts" the item "Lurasidone"; and
- (D) by inserting after the item "Tybamate" the item "Valbenazine"; and

(xviii) in the list of "**Miscellaneous:**"—

- (A) by inserting after the item "Brucine" the following items:
 - "Burosumab
 - Tert-Butyl 4-(phenylamino)piperidine-1-carboxylate (1-boc-4-AP)";
- (B) by inserting after the item "Disodium clodronate" the item "Disodium edetate";

- (C) by inserting after the item “Ergot, alkaloids of” the item “Esafoxolaner”;
- (D) by inserting after the item “Fampridine” the item “Faricimab”;
- (E) by inserting after the item “Imiquimod” the item “Inclisiran”;
- (F) by inserting after the item “Lung phospholipid” the item “Luspatercept”;
- (G) by deleting the item “Methyl(2S)-2-({1-[4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (FUB-AMB) (DD)”;
- (H) by inserting after the item “Nitrophenols, ortho, meta and para” the following items:
- “Norfentanyl
- Nusinersen”;
- (I) by inserting after the item “Pegvisomant” the item “Pemafibrate”;
- (J) by inserting after the item “Pentosan” the item “5-Pentyl-2-(2-phenylpropan-2-yl)-2,5-dihydro-1H-pyrido[4,3-b]indol-1-one (CUMYL-PEGACLONE)(DD)”;

- (K) by inserting after the item “Phenols (any member of the series of phenols of which the first member is phenol and of which the molecular composition varies from member to member by one atom of carbon and two atoms of hydrogen); compounds of phenol with a metal” the item “N-Phenyl-4-piperidinamine (4-AP)”;
- (L) by inserting after the item “Plerixafor” the item “Polidocanol”;
- (M) by inserting after the item “Sapropterin” the item “Sarolaner”;
- (N) by deleting the item “Sodium edetate”;
- (O) by inserting after the item “Sodium cromoglycate” the item “Sodium zirconium cyclosilicate”;
- (P) by inserting after the item “Sumatriptan” the item “Tafamidis”; and
- (Q) by inserting after the item “Teriparatide” the item “Tetrofosmin”.

Made 13 September 2023
[KKM.600-18/2/95; PN(PU2)172/JLD. 20]

DR. ZALIHA BINTI MUSTAFA
Minister of Health